11-Apr-2025
Novavax’s Strategic Positioning and Strong Efficacy Drive Buy Rating
TipRanks (Fri, 11-Apr 6:36 AM ET)
Novavax Faces Uncertainty Amid BLA Approval Delays and Regulatory Challenges
TipRanks (Fri, 11-Apr 5:06 AM ET)
RFK Jr. says will know by Sept. what is causing autism
Seeking Alpha News (Thu, 10-Apr 2:52 PM ET)
Biggest stock movers Thursday: KMX, DXCM, X, and more
Seeking Alpha News (Thu, 10-Apr 10:35 AM ET)
Novavax in selloff after RFK Jr.’s comments on COVID vaccine
Seeking Alpha News (Thu, 10-Apr 10:28 AM ET)
Novavax Announces Changes to Board of Directors
PRNewswire (Tue, 11-Mar 8:00 AM ET)
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
PRNewswire (Thu, 27-Feb 8:00 AM ET)
PRNewswire (Thu, 20-Feb 8:00 AM ET)
Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.
Business Wire (Thu, 23-Jan 9:00 AM ET)
NVAX Underpriced Bullish Call Spread has Profit Potential of 41%
Market Chameleon (Tue, 14-May 6:14 AM ET)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Novavax trades on the NASDAQ stock market under the symbol NVAX.
As of April 11, 2025, NVAX stock price climbed to $5.86 with 6,429,927 million shares trading.
NVAX has a beta of 1.66, meaning it tends to be more sensitive to market movements. NVAX has a correlation of 0.07 to the broad based SPY ETF.
NVAX has a market cap of $942.55 million. This is considered a Small Cap stock.
Last quarter Novavax reported $88 million in Revenue and -$.51 earnings per share. This beat revenue expectation by $4 million and met earnings estimates .
In the last 3 years, NVAX traded as high as $76.77 and as low as $3.53.
The top ETF exchange traded funds that NVAX belongs to (by Net Assets): VTI, VB, IWM, VXF, XBI.
NVAX has outperformed the market in the last year with a return of +36.3%, while the SPY ETF gained +4.5%. However, in the most recent history, NVAX shares have underperformed the stock market with its stock returning -37.1% in the last 3 month period and -16.3% for the last 2 week period, while SPY has returned -7.7% and -3.9%, respectively.
NVAX support price is $5.05 and resistance is $5.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVAX shares will trade within this expected range on the day.